Hubei Huaqiang High-Tech Co. Ltd. A

Huaqiang Technology released its 2026 interim report, with net profit attributable to the parent company of 9.53 million yuan, up 130.52% from the same period last year. Total operating revenue was 219 million yuan, up 23.21% year-on-year. Net cash inflow from operating activities was 5.78 million yuan, marking three consecutive years of growth. The company's latest asset-liability ratio was 11.28%, down 1.82 percentage points from the same period last year. The latest gross margin was 21.52%, up 2.36 percentage points year-on-year. Diluted earnings per share were 0.03 yuan, up 200.00% year-on-year.

Huaqiang Technology released its 2026 interim report, with net profit attributable to the parent company of 9.53 million yuan, up 130.52% from the same period last year. Total operating revenue was 219 million yuan, up 23.21% year-on-year. Net cash inflow from operating activities was 5.78 million yuan, marking three consecutive years of growth. The company's latest asset-liability ratio was 11.28%, gross margin was 21.52%, return on equity was 0.23%, and diluted earnings per share was 0.03 yuan.

Huaqiang Technology disclosed its earnings forecast, expecting net profit attributable to the parent for the first half of 2026 to be between 8.5 million yuan and 10.67 million yuan, representing a year-on-year increase of 105.65% to 158.15%. Deducted non-recurring profit is expected to show a loss of 12.73 million yuan to 19.09 million yuan, compared with a loss of 33.5114 million yuan in the same period last year. The company stated that the profit growth was mainly due to the optimization of the pharmaceutical packaging product structure and market expansion, with product sales volume and revenue increasing year-on-year, driving up gross margins, while quality and efficiency improvement measures achieved tangible results.